A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by rapidly progressive pulmonary hypertension. A diagnosis was made.

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

Fire season brings many hazards to our area, one of those hazards is the air pollutants from the fires. At high levels, these ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

Ambulatory cardiac monitors’ clinical and economic outcomes vary; one long-term continuous monitor brand showed greater arrhythmia diagnosis, fewer retests and cardiovascular events, and lower health ...

Reports Q2 revenue $48,000 vs. $24.1M last year. “In the second quarter, we made significant progress across our clinical and corporate goals,” said Barry Quart, Pharm.D., CEO and Director of Connect ...

Phyxiom, developer of a platform aiming to enhance asthma and COPD management, has announced its official launch.

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Roughly 14 million americans have chronic obstructive pulmonary disease, or COPD, a lung disease that can make it tough to ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...